AUTHOR=Zhang Zhedong , Huang Yu , Gu Haihua , Zhao Lufeng , Zhao Baiqin 

TITLE=Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1370666

DOI=10.3389/fonc.2024.1370666

ISSN=2234-943X

ABSTRACT=<p>The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). <italic>p.</italic>G719X and <italic>p.</italic>S768I mutations, often present in the form of complex mutations, are considered rare. This study firstly reported the treatment outcome of a locally advanced unresectable NSCLC patient with a rare complex EGFR <italic>p.</italic>G719X/<italic>p.</italic>S768I mutations who received befotertinib. After treatment, the patient achieved partial response (PR), and no severe adverse events were observed. This case report supported befotertinib as a promising treatment option for advanced NSCLC patients with the rare <italic>p.</italic>G719X/<italic>p.</italic>S768I complex mutations.</p>